You are here: Industry Insights > Bladder cancer

News List

AstraZeneca bounces back; gains US approval for bladder cancer drug biospectrumasia
May 08, 2017
The UK-based firm believes that the drug will become a “cornerstone” in their immuno-oncology portfolio and could generate more than $6.5 billion in global sales
AstraZeneca’s Imfinzi receives FDA accelerated approval for previously treated patients with advance cphi-online
May 05, 2017
Imfinzi is the cornerstone in an extensive immuno-oncology program across multiple cancer types and stages of disease.
AstraZeneca’s bladder cancer treatment receives FDA approval europeanpharmaceuticalreview
May 04, 2017
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) to treat patients with locally advanced or metastatic urothelial carcinoma (mUC).
AstraZeneca's Imfinzi Receives FDA Accelerated Approval for Previously Treated Patients with Advance americanpharmaceuticalreview
May 03, 2017
AstraZeneca and MedImmune announced the US Food and Drug Administration (FDA) granted accelerated approval to Imfinzi (durvalumab).
Bavarian Nordic announces collaboration to evaluate CV301 and Tecentriq in bladder cancer cphi-online
March 14, 2017
Collaboration is the second to evaluate a combination of CV301 with a checkpoint inhibitor.
Immunotherapy treatment fast-tracked under UK’s access to medicines scheme europeanpharmaceuticalreview
February 06, 2017
From today, UK patients with an incurable form of bladder cancer can access the new immunotherapy, atezolizumab.
FDA grants Roche's cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type worldpharmanews
January 13, 2017
Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ...

Previous page 1 2 3 4 5 Next page